RDNT Earnings

RDNT reported its earnings on 2025-11-10, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.23 by 0% . The stock experienced a 3.24% price change on the earnings day and a -6.19% change over the next five days, reflecting market reactions to the results.

Following RDNT's earnings announcement on 2025-11-10, the stock price moved by 3.24% on the day of the release. Over the subsequent five days, it saw a -6.19% change. Historically, RDNT's stock price tends to shift by an average of -4.09% in the 10 days leading up to earnings and +5.40% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate RDNT’s annual revenue to reach 515.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 1.65% and EPS estimates Revise Upward by 1.81% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between RDNT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 1.65%, while EPS estimates moved Revise Upward by 1.81% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, RDNT's stock price typically moves by -4.09% in the 10 days before its earnings and +5.40% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 515.00M.

The earnings call reveals strong financial performance, with increased revenue and EBITDA guidance, low financial leverage, and improved DSO. The Q&A section highlights growth in PET/CT volumes, expansion plans, and AI technology integration, despite some uncertainties in commercial payer adoption and labor market impacts. The positive outlook on joint ventures and virtual radiology, alongside digital health revenue growth, supports a positive sentiment. Given the market cap of approximately $4.35 billion, the stock is likely to see a positive movement, potentially between 2% to 8% over the next two weeks.